Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature

Table 4 Pooled analysis of demographic profile, prevalence of epidermal growth factor receptor mutations and disease control rates with erlotinib following prior gefitinib therapy

Female gender : 60.6% (292 of 482)

Adenocarcinoma histology: 88.3% (421 of 477)

Non smokers: 64.5% (304 of 471)

East Asian ethnicity: 92.3% (445 of 482)

EGFR mutation positive status1: 48.4% (224 of 463)

Disease control rate with prior gefitinib treatment: 79.4% (336 of 423)

Disease control rate with subsequent erlotinib treatment: 45.4% (194 of 427)

¹Indicates presence of sensitizing EGFR mutations (exon 19 deletion or exon 21 L858R mutation). EGFR: Epidermal growth factor receptor.